Recipharm Appoints General Manager
News Jan 09, 2016
Recipharm has announced that it has appointed Yves Buelens to the position of General Manager for its wholly owned new subsidiary Kaysersberg Pharmaceuticals SAS.
Yves Buelens has a Master in Pharmaceutical Sciences from the University of Brussels, Belgium and a specialization as Industrial Pharmacist (QP). He brings a broad experience to the Group acquired in various roles in the pharmaceutical industry as well as in contract manufacturing organizations in Europe. Yves has been the plant manager for the Kaysersberg facility since 2014.
Commenting on the appointment, CEO Thomas Eldered said “Yves Buelens brings valuable experience to Recipharm having worked with a variety of pharmaceutical companies including CDMO’s. I am sure he and his team will contribute greatly to the ongoing development of Recipharm and in particular with this exciting new technology”.
Yves Buelens said “I'm looking forward to become a member of the Recipharm family. I believe it will be a fruitful environment for growth and expansion of the Kaysersberg site. The long-term contract with Alcon will be an excellent foundation and milestone for other business opportunities and the proven quality track record will be the cornerstone to attract new customers. The Recipharm entrepreneurship combined with high technical skills of the Alsace workforce will give us a bright future together”.
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE
Comments | 0 ADD COMMENT
15th Symposium on the Practical Applications of Mass Spectrometry in the Biotechnology Industry
Sep 09 - Sep 12, 2018
CE in the Biotechnology & Pharmaceutical Industries: 20th Symposium on the Practical Applications for the Analysis of Proteins, Nucleotides & Small Molecules
Sep 09 - Sep 12, 2018